SIG
CRBP icon

Stanford Investment Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Stanford Investment Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-122
Closed -$31K – 59
2016
Q4 		$31K Buy
+122
New +$28K 0.02% 186

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Stanford Investment Group's CRBP Position: Q1 2017 in Review

Stanford Investment Group sold out of Corbus Pharmaceuticals (CRBP) in Q1 2017, closing a stake of 122 shares — an estimated $31K sold.

Stanford Investment Group first reported a position in CRBP in Q4 2016 and held it in 1 quarter. The position peaked at $31K in Q4 2016. 54 funds tracked by Wall St. Rank hold CRBP as of Q1 2017.

  • Stanford Investment Group reported no remaining Corbus Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 122 Corbus Pharmaceuticals shares in Q1 2017, an estimated $31K.
  • Stanford Investment Group first reported a position in Corbus Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Stanford Investment Group's Corbus Pharmaceuticals position peaked at $31K in Q4 2016.
  • 54 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.